Cover Image
市場調查報告書

血管收縮素II受體 (AT2或AGTR2) :開發中產品分析

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361645
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
血管收縮素II受體 (AT2或AGTR2) :開發中產品分析 Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 47 Pages
簡介

本報告提供血管收縮素II受體 (AT2或AGTR2)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

血管收縮素II受體 (AT2或AGTR2)的概要

治療藥的開發

血管收縮素II受體 (AT2或AGTR2):開發中的產品 - 各開發階段

血管收縮素II受體 (AT2或AGTR2):開發中的產品 - 各治療範圍

血管收縮素II受體 (AT2或AGTR2):開發中的產品 - 各適應症

血管收縮素II受體 (AT2或AGTR2):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

血管收縮素II受體 (AT2或AGTR2):企業開發中的產品

血管收縮素II受體 (AT2或AGTR2):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

血管收縮素II受體 (AT2或AGTR2)的治療藥的開發企業

  • CJ HealthCare Corp.
  • MorphoSys AG
  • Novartis AG
  • Vicore Pharma AB

藥物簡介

血管收縮素II受體 (AT2或AGTR2):暫停中的計劃

血管收縮素II受體 (AT2或AGTR2):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0566TDB

Summary

Global Markets Direct's, 'Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2016', provides in depth analysis on Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
  • The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Overview
  • Therapeutics Development
    • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Stage of Development
    • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Therapy Area
    • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Indication
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Companies
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
    • CJ HealthCare Corp.
    • MorphoSys AG
    • Novartis AG
    • Vicore Pharma AB
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
  • (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EMA-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOR-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-6A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Projects
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Featured News & Press Releases
    • Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys's Dutch Lanthipeptide Subsidiary
    • Aug 01, 2016: Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF
    • Jun 30, 2016: New research data with C21 on diabetes
    • Jun 15, 2016: Prestigious award for UQ superstar scientist
    • Jun 13, 2016: Successful conclusion of the first Phase I study with C21
    • Feb 10, 2015: Spinifex Pharmaceuticals Enhances CMC Team With Two Senior Appointments
    • May 21, 2014: Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis
    • Feb 05, 2014: Spinifex Pharmaceuticals' Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia
    • Oct 18, 2013: Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch
    • Mar 27, 2013: Spinifex Pharma Receives AUD1.5m In R&D Tax Incentive For Research Activities Related To Discovery Of Treatments For Pain
    • Feb 18, 2013: Vicore Pharma Announces Publication Of Article In Nature
    • Dec 10, 2012: Spinifex Pharma Starts Phase II Proof-of-concept Trial Of EMA401 In Chemotherapy-induced Peripheral Neuropathy
    • Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting
    • Nov 15, 2012: Vicore Pharma Announces Publication Of Study Results Of C21 In Spinal Cord Injury In Journal Neurobiology Of Disease
    • Aug 28, 2012: Spinifex Pharma Announces Positive Phase II Results For EMA401 In Postherpetic Neuralgia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by CJ HealthCare Corp., H2 2016
  • Pipeline by MorphoSys AG, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Vicore Pharma AB, H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top